Trimel Pharmaceuticals Corporation Announces Appointment of New Director

TORONTO, ONTARIO–(Marketwired – Apr 30, 2013) –
Trimel Pharmaceuticals Corporation (TSX:TRL) is
pleased to announce the appointment of Dr. Lorne Tyrrell to its
Board of Directors.

Dr. Tyrrell has had a distinguished medical career, with
numerous research achievements particularly in the field of
virology and antiviral research. Dr. Tyrrell is presently a
professor in the Department of Medical Microbiology and Immunology
at the University of Alberta Faculty of Medicine and Dentistry and
is a founding director of the Li Ka Shing Institute of Virology at
the University of Alberta. Dr. Tyrrell is a recipient of over forty
awards and honours, including the Order of Canada and Alberta Order
of Excellence, and is a member of the Canadian Medical Hall of
Fame. Additionally, Dr. Tyrrell has been active in numerous
business ventures in the pharmaceutical industry and has previously
served, or is currently serving, on the boards of directors of
other publicly traded companies.

“The addition of Dr. Tyrrell to the Board of Directors is a very
positive event for Trimel,” said Bruce Brydon, Chairman of the
Board. “With his long and esteemed career in medical research and
deep pool of scientific knowledge, we believe he is an excellent
addition to the Board and will help to further Trimel’s development
and growth. We are extremely excited to move forward with Dr.
Tyrrell as part of the Board.”

About Trimel

Trimel is a specialty pharmaceutical company actively developing
medications for male hypogonadism, female sexual dysfunction and
various respiratory disorders. CompleoTRT™, a product
utilizing Trimel’s licensed bioadhesive intranasal gel technology,
has been filed with the FDA for regulatory approval in the United
States. For more information, please visit

Trimel Pharmaceuticals Corporation

Kenneth G. Howling

Chief Financial Officer

(416) 679-0536